To evaluate the availability of intra-erythrocytic oxaliplatin and plasma oxaliplatin for patients who received oxaliplatin containing adjuvant chemotherapy

To evaluate the availability of intra-erythrocytic oxaliplatin and plasma oxaliplatin for patients who received oxaliplatin containing adjuvant chemotherapy - To evaluate the availability of intra-erythrocytic oxaliplatin and plasma oxaliplatin for patients who received oxaliplatin containing adjuvant chemotherapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009128

Enrollment

Registered

2012-10-16

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Stage II/III colon cancer (2)Consent has already been obtained about receiving the adjuvant chemotherapy containing oxaliplatin

Exclusion criteria

Exclusion criteria: (1)Prior chemotherapy including platinum drugs (2)HBs antigen positive, HCV antibody positive, HIV antibody positive, TPHA positive, and the active infection which needs systemic treatment (3)History of psychological disease or central nervous system disorders (4)No intention of cooperating with clinical tests in this study (5)Current or prospective enrolled in placebo controlled trial for peripheral neuropathy (6) Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Contacts

Public ContactHirohiko Sato

Tokushima University Hospital Department of Digestive and Pediatric Surgery

088-631-3111

Outcome results